Laboratory of Genomics and Transcriptomics
+39 050 8753553
Glioblastoma (GBM) is the most malignant type of primary brain tumor, with a worse prognosis, high mortality and a median survival of 12-14 months following diagnosis. Surgical resection of GBM has only limited effectiveness due to high invasiveness of tumor cells that infiltrate the surrounding brain tissue and cause disease recurrence, with inherent drug resistance of cancer cells rendering the adjuvant chemo- and radiotherapy insufficient to eliminate the invasive cells.
Prospero Civita is involved to investigate tumor heterogeneity in glioblastoma by studying temporal and spatial evolution in human GBM specimens.Understanding and characterizing heterogeneity can allow for a better explanation of the causes and progression of disease. In turn, this has the potential to guide the investigation of broader and more specific niche of potential new biomarkers or therapeutic targets and the creation of more refined treatment strategies.
He received is Master’s degree in Health Biology at the University of Siena.
Prospero Civita is a Student of the PhD program in Clinical and Translational Science of the University of Pisa and spends most of his research time at the FPS Institute in the Genomic Section, under the supervision of Sara Franceschi.